Know Cancer

forgot password

INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations

18 Years
Open (Enrolling)
Lung Cancer

Thank you

Trial Information

INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations

If a subject have lung cancer or another cancer carrying a T790M mutation in the EGFR gene,
he/she may be eligible to participate in this research study. To determine eligibility, a
subject will need to perform the following steps: provide informed consent, fill out the
study questionnaire and provide medical records documentation.

The study questionnaire should take about 30 minutes to complete. The questionnaire asks for
information on personal and family cancer and health history. The information provided will
help investigators to determine which parts of the study a subject is eligible for. A few
weeks after submitting the questionnaire, a member of the research study team will contact
the subject by telephone to clarify any questions about the response.

For medical records documentation investigators will request permission to obtain and review
medical records pertaining to any personal history of cancer. Subjects will need to complete
a medical record release form to allow investigators to collect medical records regarding
prior cancers and cancer treatment.

After a subject is determined to be eligible, he/she will have a conversation with a genetic
counselor regarding the potential risks, benefits and limitations of genetic testing. A
genetic counselor is an expert in the field of inherited disorders. They work as members of
the health care team and act as a patient advocate providing education and support to the
patient, family and the medical team. If a subject agrees to proceed, he/she will be
provided a kit (by mail or in person) to provide a saliva sample for genetic testing. This
involves spitting into a special container provided by the study. This sample will be sent
to a clinically-certified testing laboratory to determine presence of an inherited EGFR

Once the results have been determined, the subject will receive a letter with the phone
number of a genetic counselor to call in order to review results of the genetic testing.
Alternatively, a subject can decide not to receive the results of the genetic testing and
can note that on the letter received and send it back to the study team instead of calling
for the results.

If a mutation is found in the saliva sample, a subject will receive information about how to
undergo confirmatory testing of a blood specimen. This can be done at a local laboratory
using a kit that will be mailed. When the results are available a genetic counselor will
call to discuss them. If the confirmatory blood test confirms an inherited mutation,
subjects will receive instructions on how to invite family members to be tested if

Investigators will collect material from a prior tumor biopsy (if available), copies of
imaging scans, and medical records to study. The copies of imaging scans will allow study of
the characteristics of nodules in the lungs. This information will be used to answer
additional questions about cancers carrying EGFR T790M mutations.

It will only take a few months to complete the main part of the study. After that, subjects
will be followed every 6 months for 2 years. If a subject allows a piece of a tumor specimen
or DNA to be stored for future investigational studies, then he/she will remain enrolled in
research for as long as the specimen is stored in the specimen bank.

Inclusion Criteria:

- Diagnosis of cancer of any type with an EGFR T790M mutation identified on genotyping
of cancer; or

- Have a first degree relative known to carry a germline EGFR mutation; or

- Have a known germline EGFR mutation

Exclusion Criteria:

- Subjects with lung cancer and an acquired T790M mutation first detected after
exposure to an EGFR tyrosine kinase inhibitor such as erlotinib or gefitinib

- Too ill to complete the study questionnaire or provide the necessary specimen for

- Unable to give informed consent

- Unable to speak or read English

Type of Study:

Observational [Patient Registry]

Study Design:

Observational Model: Family-Based, Time Perspective: Prospective

Outcome Measure:

Prevalence of EGFR mutations

Outcome Description:

To determine the prevalence of germline EGFR mutations in lung cancer patients with EGFR T790M mutations in their tumor and in first-degree relatives of carriers of germline EGFR mutations

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Geoffrey Oxnard, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Institutional Review Board

Study ID:




Start Date:

December 2012

Completion Date:

Related Keywords:

  • Lung Cancer
  • Gene Mutation
  • Lung Neoplasms



Dana-Farber Cancer Institute Boston, Massachusetts  02115